Introduction {#S1}
============

*Candida dubliniensis* is a commensal of the oral cavity but can also colonize other anatomical sites ([@B9]). Furthermore, it can cause oropharyngeal candidiasis, mainly in HIV-positive patients ([@B22]; [@B9]), and invasive candidiasis ([@B14]). *C. dubliniensis* is closely related to *Candida albicans* ([@B22]). *C. albicans* and *C. dubliniensis* share the same *in vitro* antifungal susceptibility patterns ([@B16]; [@B10]). The clinical breakpoints (CBs) and Epidemiological Cut-Off values (ECOFFs), determined by CLSI/EUCAST reference methods or commercial methods are similar ([@B15]; [@B6]^[1](#footnote1){ref-type="fn"}^). Acquired resistance to antifungal has been reported in *C. dubliniensis* just as in *C. albicans* ([@B13]; [@B4]; [@B17]), but less frequently ([@B16]). Until recently, identification of *C. dubliniensis* was difficult in the clinical laboratories because it shares C. *albicans* phenotypic characteristics ([@B22]; [@B9]). Things changed with the use of Matrix-Assisted Laser Desorption Ionization--Time of Flight (MALDI-TOF), which can easily differentiate the two species ([@B18]). There are some striking differences between *C. albicans* and *C. dubliniensis*. First, their ecological niches are different. Unlike *C. albicans*, *C. dubliniensis* is uncommon in the gastro-intestinal tract of healthy individuals, but for the oral cavity ([@B21]). Second, there are major difference in term of pathogenicity, *C. albicans* being more pathogenic ([@B12]).

Recently, we also observed differential growth patterns between *C. albicans* and *C. dubliniensis* when they are tested by Etest for susceptibility to fluconazole and echinocandins. With *C. dubliniensis*, a trailing effect (incomplete growth inhibition at supra-MICs) was observed with echinocandins but not with fluconazole, while for *C. albicans* the opposite pattern was seen. To further assess these differences between the two species, we analyzed, here, the growing patterns of a large panel of clinical isolates of the two species when tested against fluconazole and two echinocandins by the reference EUCAST technique and by Etest.

Materials and Methods {#S2}
=====================

To study the growth of *C. albicans* and *C. dubliniensis* in the presence of fluconazole, caspofungin or micafungin, a total number of 30 *C. albicans* and 30 *C. dubliniensis* clinical epidemiologically not related isolates were selected from the mycology's laboratories of Necker and Georges Pompidou University hospitals. None of these strains were known to be resistant to echinocandins or azoles.

These 60 isolates were tested using two different methods: the EUCAST EDef 7.3 microdilution procedure and the Etest agar diffusion method (Biomérieux, Marcy-l'Étoile, France). The yeasts were first cultured on BBL CHROMagar Candida plate (Becton Dickinson GmbH, Heidelberg, France) for primary identification and then identified by MALDI-TOF spectrometry (microflex LT, Bruker Daltonik GmbH, Germany).

Antifungal susceptibility testing by EUCAST was performed according to the reference method ([@B1]) in RPMI 1640 medium buffered to pH 7.0 with morpholino-propanesulfonic acid (MOPS) and supplemented with glucose to a final concentration of 2%. The final inoculum was 0.5--2.5 10^5^ CFU/ml. *Candida krusei* ATCC 6258 and *Candida parapsilosis* ATCC 22019 isolates were used as quality control strains. Spectrophotometric reading was performed after incubation at 35°C, and MICs were determined with a 50% inhibition endpoint. The percentage of growth was determined compared to the drug-free control. The trailing effect was defined as a reduced but persistent (≥5%) growth (G) above the MIC of the isolate, at least in four consecutive wells. Consequently, two groups of trailing effect were defined depending on G, as previously described ([@B20]): moderate trailing for G between 5 and 25%, strong trailing when G is \>25 but \<50%,

Antifungal susceptibility testing by Etest was performed according to manufacturer's instructions ([@B3]). The presence of microcolonies in the ellipse of inhibition after incubation at 35°C defined the trailing effect and was not indicative of resistance. Due to the subjective nature of the visual reading, the level of the trailing effect was not categorized by the Etest method.

For both techniques ([@B7]) reading was performed at 24 and 48 h. Indeed, for Etest the period incubation depends on the growth and could be 24 h and/or 48 h. Moreover, it is recommended to read at 48 h for detection of some phenomenon such as heteroresistance. For these reasons, Etest reading is often performed both at 24 and 48 h. Therefore, we also determined MICs by EUCAST at 24 h and 48 h.

Results {#S3}
=======

With Etest, MIC values at 24 h determined for fluconazole, micafungin, and caspofungin for *C. albicans* ranged from 0.06 to 0.25 μg/ml \[Geometric mean (GM) = 0.14 μg/ml\], from 0.008 to 0.016 (GM = 0.009 μg/ml), and from 0.03 to 0.25 μg/ml (GM = 0.09 μg/ml), respectively, while for *C. dubliniensis* MICs ranged from 0.03 to 0.5 (GM = 0.09 μg/ml), from 0.008 to 0.016 (GM = 0.01 μg/ml), and from 0.03 to 0.25 (GM = 0.12 μg/ml), respectively. MIC distributions determined by Etest at both 24 h and 48 h are presented in [Table 1](#T1){ref-type="table"}.

###### 

MIC distribution of fluconazole, caspofungin and micafungin against *C. albicans* and *C. dubliniensis* by EUCAST and Etest methods.

  **Antifungal**                                                                      
  ------------------- -------- ------ ----- ---- ---- --- ---- ---- ---- ---- --- --- --
  *C. albicans*       EUCAST   24 h   FCZ                      14   14   2            
  *C. dubliniensis*                                            23   5    1        1   
  *C. albicans*       EUCAST   24 h   CAS                      8    21   1            
  *C. dubliniensis*                                            8    16   6            
  *C. albicans*       EUCAST   24 h   MIC        30                                   
  *C. dubliniensis*                              30                                   
  *C. albicans*       EUCAST   48 h   FCZ                      13   17                
  *C. dubliniensis*                                            22   4    1        1   
  *C. albicans*       EUCAST   48 h   CAS                      5    21   4            
  *C. dubliniensis*                                            6    11   12   1       
  *C. albicans*       EUCAST   48 h   MIC        26   3   1                           
  *C. dubliniensis*                              26   3   1                           
  *C. albicans*       Etest    24 h   FCZ                 2    20   8                 
  *C. dubliniensis*                                   2   13   12   2    1            
  *C. albicans*       Etest    24 h   CAS             3   9    17   1                 
  *C. dubliniensis*                                   1   3    24   2                 
  *C. albicans*       Etest    24 h   MIC   25   5                                    
  *C. dubliniensis*                         15   15                                   
  *C. albicans*       Etest    48 h   FCZ                 2    15   13                
  *C. dubliniensis*                                   1   13   13   1    2            
  *C. albicans*       Etest    48 h   CAS                 9    15   6                 
  *C. dubliniensis*                                       3    18   9                 
  *C. albicans*       Etest    48 h   MIC   20   10                                   
  *C. dubliniensis*                         6    21   3                               

With fluconazole, a trailing effect was observed with Etest for 93.3% of *C. albicans* isolates while no trailing was seen with the two echinocandins ([Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). In contrast, for the *C. dubliniensis* isolates, trailing was not observed with fluconazole, while trailing was observed for echinocandins in 86.7% and 90% of the isolates for micafungin and caspofungin, respectively ([Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). In order to confirm that the differential pattern of growth was not related to the susceptibility testing method used, all the strains were also tested by EUCAST ([Table 1](#T1){ref-type="table"}). MICs determined by EUCAST were within ± 2 log~2~ dilutions of the Etest MICs in \>98% of the cases.

###### 

Trailing observed for fluconazole, micafungin, and caspofungin against *C. albicans* and *C. dubliniensis* by EUCAST and Etest methods.

  **Method**   **Species**         **Trailing**   **% of isolates with trailing**                              
  ------------ ------------------- -------------- --------------------------------- ------ ----- ------ ------ ------
  EUCAST       *C. albicans*       Moderate       20                                16.7   0     0      0      0
                                   Strong         73.3                              73.3   0     6.7    0      0
                                   Total          93.3                              90     0     6.7    0      0
               *C. dubliniensis*   Moderate       16.7                              6.7    6.7   40     3.3    16.7
                                   Strong         10                                13.3   0     16.7   10     33.3
                                   Total          26.7                              20     6.7   56.7   13.3   50
  Etest        *C. albicans*       Total          43.3                              93.3   0     0      0      0
               *C. dubliniensis*   Total          0                                 0      3.3   86.7   6.7    90

![Inhibition pattern by Etest for fluconazole, caspofungin, and micafungin for the strain *C. albicans* HEGP 7043 **(A--C)** and *C. dubliniensis* HEGP 6443 **(D--F)**. FL, fluconazole; CS, caspofungin; MYC, micafungin.](fmicb-11-01286-g001){#F1}

The inhibition patterns obtained with Etest, were also observed by EUCAST for *C. albicans* and *C. dubliniensis* ([Table 2](#T2){ref-type="table"}). Indeed, for fluconazole, the trailing was seen for *C. albicans* and not for *C. dubliniensis* while the opposite pattern was observed with echinocandins. For *C. albicans*, 90% of the isolates exhibited a trailing effect for fluconazole while only 6.7%, and 0% of the isolates showed a trailing for micafungin, and caspofungin, respectively. For *C. dubliniensis* only 20% of the isolates showed a trailing effect for fluconazole, while 56.7%, and 50% of isolates exhibited a trailing effect for micafungin and caspofungin, respectively ([Table 2](#T2){ref-type="table"}). All together, these data clearly demonstrated that the trailing is species specific. [Figure 2](#F2){ref-type="fig"} showed an example of the trailing effect observed for one isolate each of *C. albicans* and *C. dubliniensis* for the three antifungal agents.

![Inhibition pattern by EUCAST in presence of fluconazole **(A)**, caspofungin **(B)**, and micafungin **(C)** for the strains *C. albicans* HEGP 7043 and *C. dubliniensis* HEGP 6409. MICs correspond to the lowest antifungal concentration for which the growth is \<50%. Trailing correspond to a growth between 5 and 49%. Black horizontal line represents the 5% growth threshold.](fmicb-11-01286-g002){#F2}

The level of trailing effect was always of strong intensity (according to the definition) except for micafungin with *C. dubliniensis* isolates for which a moderate trailing was mostly observed ([Table 2](#T2){ref-type="table"}).

Discussion {#S4}
==========

Although *C. albicans* and *C. dubliniensis* are closely related phylogenetically ([@B22]) and exhibit the same antifungal susceptibility patterns, we found that they behave differently *in vitro* in presence of fluconazole or echinocandins. For *C. albicans*, a trailing phenomenon was observed with fluconazole and not for the echinocandin, while for *C. dubliniensis*, the opposite pattern of growth was seen (i.e., no trailing with fluconazole and trailing with echinocandins). Differential *in vitro* response to echinocandin and azole antifungal agents between *C. albicans* and *C. dubliniensis* has been previously reported by EUCAST and CLSI methods ([@B2]; [@B8]). Our results are in accordance with these previous reports and show that the phenomenon is also present when isolates are tested by a completely different method (i.e., Etest, an agar diffusion method), therefore not dependent on the technique.

Trailing effect of *C. albicans* to fluconazole is well known ([@B5]; [@B11]; [@B19]) and may have a clinical impact ([@B19]). Here we observed that this effect is not present for the sibling species *C. dubliniensis*. Altogether, these findings could suggest that the pathways involved in the trailing effect may be different in the two species. The comparative study of these two species may help deciphering the mechanisms involved in tolerance in *C. albicans*.

Finally, our findings are important for the clinical microbiology laboratories and clinical care. Indeed, the trailing observed when echinocandins are tested against *C. dubliniensis* should be known and the corresponding strains should not be considered as resistant pattern to these important drugs.
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